Clinical Pharmacologist | Gastroenterologist
Professor Murray Barclay is a clinical pharmacologist, gastroenterologist, and clinical professor with the University of Otago, Christchurch. His research interests include inflammatory bowel disease genetics and pharmacogenetics, optimising medicines in gastroenterology and rheumatology, immune modulating drugs, and drug concentration monitoring.
He developed Interactive Clinical Pharmacology (www.icp.org.nz) with graphical web-based modules for teaching clinical pharmacology.
Publications
Butler, J. M., Frampton, C. M., Moore, G., Barclay, M. L., & Jardine, D. L. (2023). Immediate effect of caffeine on sympathetic nerve activity: Why coffee is safe? A single-centre crossover study. Clinical Autonomic Research. Advance online publication. doi: 10.1007/s10286-023-00967-5
Journal - Research Article
Wang, M., Barclay, M. L., Chin, P. K. L., & Doogue, M. P. (2023). Changes in inpatient medicine prescribing during Covid-19 lockdown. Internal Medicine Journal, 53, 917-922. doi: 10.1111/imj.15996
Journal - Research Article
Kee, P. S., Maggo, S. D. S., Kennedy, M. A., Barclay, M. L., Miller, A. L., Lehnert, K., … Chin, P. K. L. (2022). Omeprazole treatment failure in gastroesophageal reflux disease and genetic variation at the CYP2C locus [Brief research report]. Frontiers in Genetics, 13, 869160. doi: 10.3389/fgene.2022.869160
Journal - Research Other
Kubovy, J., & Barclay, M. L. (2022). Helicobacter pylori in New Zealand: Current diagnostic trends and related costs. New Zealand Medical Journal, 135(1562), 48-55. Retrieved from https://journal.nzma.org.nz/
Journal - Research Article
Crouwel, F., Simsek, M., van Doorn, A. S., Mulder, C. J. J., Buiter, H. J. C., Barclay, M. L., … de Boer, N. K. (2022). Rectally administrated thioguanine for distal ulcerative colitis: A multicenter case series [Brief report]. Inflammatory Bowel Diseases. Advance online publication. doi: 10.1093/ibd/izac195
Journal - Research Other
Begg, E., Barclay, M., Vella-Brincat, J., Gardiner, S. J., Doogue, M., McDermott, L., … Chambers, S., & Murdoch, D. (Eds.). (2004). Preferred Medicines List (8th ed.). Christchurch: The Caxton Press, 172p.
Edited Book - Other
Frizelle, F., & Barclay, M. (2008). Constipation in adults. In C. Young (Ed.), Clinical evidence handbook: The international source of the best available evidence for effective health care. (pp. 167). UK: BMJ: Evidence Centre.
Chapter in Book - Other
Butler, J. M., Frampton, C. M., Moore, G., Barclay, M. L., & Jardine, D. L. (2023). Immediate effect of caffeine on sympathetic nerve activity: Why coffee is safe? A single-centre crossover study. Clinical Autonomic Research. Advance online publication. doi: 10.1007/s10286-023-00967-5
Journal - Research Article
Wang, M., Barclay, M. L., Chin, P. K. L., & Doogue, M. P. (2023). Changes in inpatient medicine prescribing during Covid-19 lockdown. Internal Medicine Journal, 53, 917-922. doi: 10.1111/imj.15996
Journal - Research Article
Kubovy, J., & Barclay, M. L. (2022). Helicobacter pylori in New Zealand: Current diagnostic trends and related costs. New Zealand Medical Journal, 135(1562), 48-55. Retrieved from https://journal.nzma.org.nz/
Journal - Research Article
Liu, Z., Julsgaard, M., Zhu, X., Martin, J., Barclay, M., Cranswick, N., … Gearry, R., … the CARINA Study Group. (2022). Timing of live attenuated vaccination in infants exposed to infliximab or adalimumab in utero: A prospective cohort study in 107 children. Journal of Crohn's & Colitis, 16, 1835-1844. doi: 10.1093/ecco-jcc/jjac093
Journal - Research Article
Thomas, P. W. A., Chin, P. K. L., & Barclay, M. L. (2021). A nationwide survey on therapeutic drug monitoring of anti-tumour necrosis factor agents for inflammatory bowel disease. Internal Medicine Journal, 51(3), 341-347. doi: 10.1111/imj.14778
Journal - Research Article
Chin, P. K. L., Chuah, Q., Crawford, A. M., Clendon, O. R., Drennan, P. G., Dalrymple, J. M., Barclay, M. L., & Doogue, M. P. (2020). Clinical decision support in a hospital electronic prescribing system informed by local data: Experience at a tertiary New Zealand centre. Internal Medicine Journal, 50, 1225-1232. doi: 10.1111/imj.14706
Journal - Research Article
McCombie, A., Walmsley, R., Barclay, M., Ho, C., Langlotz, T., Regenbrecht, H., Gray, A., … Inns, S., & Schultz, M. (2020). A noninferiority randomized clinical trail of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory Bowel Diseases, 26(7), 1098-1109. doi: 10.1093/ibd/izz252
Journal - Research Article
Stamp, L. K., Chapman, P. T., Barclay, M., Horne, A., Frampton, C., Merriman, T. R., Wright, D. F. B., … Dalbeth, N. (2020). Relationships between allopurinol dose, oxypurinol concentration and urate-lowering response: In search of a minimum effective oxypurinol concentration. Clinical & Translational Science, 13, 110-115. doi: 10.1111/cts.12686
Journal - Research Article
van Doorn, A. S., Meijer, B., Frampton, C. M. A., Barclay, M. L., & de Boer, N. K. H. (2020). Systematic review with meta-analysis: SARS-CoV-2 stool testing and the potential for faecal-oral transmission. Alimentary Pharmacology & Therapeutics, 52, 1276-1288. doi: 10.1111/apt.16036
Journal - Research Article
Barclay, M. L., Karim, S., Helms, E. T. J., Keating, P. E., Hock, B., Stamp, L. K., & Schultz, M. (2019). Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays. Internal Medicine Journal, 49, 513-518. doi: 10.1111/imj.14064
Journal - Research Article
International Multiple Sclerosis Genetic Consortium, including Mason, D., & Barclay, M. (2019). Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science, 365, eaav7188. doi: 10.1126/science.aav7188
Journal - Research Article
Romagnoni, A., Jégou, S., Van Steen, K., Wainrib, G., Hugot, J.-P., and International Inflammatory Bowel Disease Genetics Constortium (IIBDGC), including Barclay, M., Gearry, R., & Roberts, R. L. (2019). Comparative performances of machine learning methods for classifying Crohn Disease patients using genome-wide genotyping data. Scientific Reports, 9, 10351. doi: 10.1038/s41598-019-46649-z
Journal - Research Article
Stamp, L. K., O'Donnell, J. L., Frampton, C., Drake, J., Zhang, M., Barclay, M., & Chapman, P. (2019). A pilot randomized controlled double-blind trial of high- versus low-dose weekly folic acid in people with rheumatoid arthritis receiving methotrexate. Journal of Clinical Rheumatology, 25(7), 284-287. doi: 10.1097/RHU.0000000000000848
Journal - Research Article
Chambers, C. N. L., Frampton, C. M. A., McKee, M., & Barclay, M. (2018). 'It feels like being trapped in an abusive relationship': Bullying prevalence and consequences in the New Zealand senior medical workforce: A cross-sectional study. BMJ Open, 8(3), e020158. doi: 10.1136/bmjopen-2017-020158
Journal - Research Article
Momozawa, Y., Dmitrieva, J., Théātre, E., Deffontaine, V., Rahumouni, S., Charloteaux, B., … The International IBD Genetics Consortium, including Barclay, M., … Georges, M. (2018). IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes. Nature Communications, 9(1), 2427. doi: 10.1038/s41467-018-04365-8
Journal - Research Article
Munning-Schmidt, E., Zhang, M., Mulder, C. J., & Barclay, M. L. (2018). Late-onset rise of 6-MMP metabolites in IBD patients on azathioprine or mercaptopurine. Inflammatory Bowel Diseases, 24(4), 892-896. doi: 10.1093/ibd/izx081
Journal - Research Article
Roberts, R. L., Wallace, M. C., Seinen, M. L., van Bodegraven, A. A., Krishnaprasad, K., Jones, G. T., van Rij, A. M., … Kennedy, M. A., … Gearry, R. B., … Barclay, M. (2018). Nonsynonymous polymorphism in guanine monophosphate synthetase is a risk factor for unfavorable thiopurine metabolite ratios in patients with inflammatory bowel disease. Inflammatory Bowel Diseases, 24(12), 2606-2612. doi: 10.1093/ibd/izy163
Journal - Research Article
Stamp, L. K., Chapman, P. T., Barclay, M. L., Horne, A., Frampton, C., Tan, P., … Dalbeth, N. (2018). How much allopurinol does it take to get to target urate? Comparison of actual dose with creatinine clearance-based dose. Arthritis Research & Therapy, 20, 255. doi: 10.1186/s13075-018-1755-0
Journal - Research Article
Stamp, L. K., Chapman, P. T., Barclay, M., Horne, A., Frampton, C., Tan, P., … Dalbeth, N. (2018). Can we predict inadequate response to allopurinol dose escalation? Analysis of a randomised controlled trial. Rheumatology, 57(12), 2183-2189. doi: 10.1093/rheumatology/key237
Journal - Research Article
Wright, D. F. B., Dalbeth, N., Phipps-Green, A. J., Merriman, T. R., Barclay, M. L., Drake, J., … Stamp, L. K. (2018). The impact of diuretic use and ABCG2 genotype on the predictive performance of a published allopurinol dosing tool. British Journal of Clinical Pharmacology, 84(5), 937-943. doi: 10.1111/bcp.13516
Journal - Research Article
Chambers, C., Frampton, C., & Barclay, M. (2017). Presenteeism in the New Zealand senior medical workforce: A mixed-methods analysis. New Zealand Medical Journal, 130(1449), 10-21. Retrieved from https://www.nzma.org.nz/journal
Journal - Research Article
Kannangara, D. R. W., Graham, G. G., Wright, D. F. B., Stocker, S. L., Portek, I., Pile, K. D., Barclay, M. L., … Stamp, L. K., & Day, R. O. (2017). Individualising the dose of allopurinol in patients with gout. British Journal of Clinical Pharmacology, 83(9), 2015-2026. doi: 10.1111/bcp.13307
Journal - Research Article
Mitrev, N., Vande Casteele, N., Seow, C. H., Andrews, J. M., Connor, S. J., Moore, G. T., Barclay, M., … IBD Sydney Organisation, and the Australian Inflammatory Bowel Diseases Consensus Working Group. (2017). Review article: Consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Alimentary Pharmacology & Therapeutics, 46(11-12), 1037-1053. doi: 10.1111/apt.14368
Journal - Research Article